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Abstract Human acidic proline-rich salivary protein PRP-1
and its C-terminally truncated form PRP-3 were analyzed by
electrospray tandem mass spectrometry. Post-translational
modifications were detected and characterized. A pyroglutamic
acid residue was demonstrated at the N-terminus, Ser-8 and Ser-
22 were shown to be phosphorylated and an O-linked glucuronic
acid conjugation was identified. The latter modification was
located to Ser-17 and found to be present in approximately 40%
of the polypeptides. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Acidic proline-rich proteins (PRPs) are the predominant
proteins in saliva. They are polymorphic with multiple func-
tions in bio¢lm formation and innate immunity [1,2]. PRP-1
consists of 150 residues (Fig. 1) and PRP-3 is its C-terminally
truncated 106 residue form [3^5]. The 30 residue N-terminal
domain of acidic PRPs contains negatively charged amino
acids and phosphorylations at Ser-8 and Ser-22 [3^5]. The
N-terminal region binds calcium, mediates adsorption to hy-
droxyapatite and regulates calcium-phosphate homeostasis
[1,2]. The C-terminal ProGln-sequence of PRP-1 mediates ad-
hesion to commensal Actinomyces and Streptococcus species
[6]. The Pro-rich middle domain promotes binding to and
inactivation of ingested plant polyphenols (tannines) [1,2].
After secretion, the acidic PRPs are rapidly enriched on
tooth surfaces and degraded as a consequence of bacterial
proteolysis [7]. Recently, cleavage of acidic PRPs by a prolyl
endoprotease activity of commensal Streptococcus and Actino-
myces species was suggested to release an ArgGlyArgProGln
pentapeptide that counteracts lactate production and desorbs
bound bacteria [8].
Secreted proteins commonly contain N- and O-linked sac-
charides [9]. The human acidic PRPs are considered non-gly-
cosylated proteins [5], although possible glycosylation has
been noted [10]. Furthermore, acidic PRPs from rat saliva
stimulated by L-adrenergic agonists are glycosylated, predom-
inantly by glucuronic acid [11].
The aim of the present work was to investigate post-trans-
lational modi¢cations in human acidic PRPs. To this end, we
used nano-electrospray (nano-ES) tandem mass spectrometry
with a hybrid quadrupole time-of-£ight (QTOF) instrument.
2. Materials and methods
2.1. Isolation and tryptic digestion of PRP-1 and PRP-3
PRP-1 and PRP-3 were isolated from parotid saliva from three
subjects (two normal and one with psoriasis and asthma on intermit-
tent medication with Bricanyl, a L2-adrenergic agonist, Draco). Paro-
tid saliva (50 ml), collected by Lashley cups under mild acidic stim-
ulation, was diluted (1:1, v/v) with 25 mM NaCl in 50 mM Tris^HCl,
pH 8.0, and separated by DEAE^Sephacel chromatography (15U1.6
cm, Pharmacia) using a linear gradient of 25 to 1000 mM NaCl in
50 mM Tris^HCl, pH 8.0. The acidic PRP fraction was concentrated
(Centriprep 10 concentrator, Amicon) and subjected to gel ¢ltration
(HiLoad 26/60 Superdex S-200 Prep grade, Pharmacia) in 20 mM
Tris^HCl, pH 8.0, containing 500 mM NaCl. The PRP-1 and
PRP-3 fractions collected were dialyzed against 50 mM Tris^HCl,
pH 8.0 (Spectra/Pore membrane No. 4, Spectrum Medical Industries)
and further puri¢ed on a Macroprep high Q column (15U1.6 cm, Bio-
Rad) using a linear gradient of 25 to 1000 mM NaCl in 50 mM Tris^
HCl, pH 8.0. The pure proteins were extensively dialyzed against
water, lyophilized and stored at 320‡C.
Puri¢ed PRP-1 and PRP-3 were digested with modi¢ed trypsin
(Promega) at an enzyme-to-substrate ratio of 1:10 (w/w) in 0.1 M
ammonium bicarbonate for 4 h at 37‡C. The reaction was quenched
by addition of a few Wl of 30% formic acid.
An aliquot of the tryptic digest was separated by HPLC using an
Aº KTA explorer system (Pharmacia Biotech) equipped with a Hypersil
Peptide C18 column (4.6U100 mm) (Pharmacia Biotech). A linear
gradient of CH3CN (0^67%, 60 min) in 0.1% aqueous tri£uoroacetic
acid (TFA) was employed at a £ow rate of 1.2 ml/min (detection at
215 nm). The remainder of the digest was available for mass spectro-
metric analysis. Before mass spectrometry, the tryptic peptide solution
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Fig. 1. Polypeptide structure of PRP-1 and PRP-3 [3^5]. PRP-3 is a
C-terminally truncated form that corresponds to the ¢rst 106 resi-
dues. Tryptic peptides of PRP-1 are indicated (T1^T7) and Ser phos-
phorylation sites are shown (H2PO3). The glutamic acid residue at
the N-terminus was cyclized to form a pyrrolidonecarboxylic acid
(pyroglutamic acid).
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was diluted with 50% aqueous methanol to give an approximate con-
centration of 1 pmol/Wl.
2.2. Mass spectrometry
Nano-ES mass spectra were recorded using a QTOF tandem mass
spectrometer [12] (Micromass). The instrument was equipped with an
orthogonal sampling ES-interface (Z-spray, Micromass). Gold coated
nano-ES needles (Protana) were used and manually opened on the
stage of a light microscope to give a spraying ori¢ce of about 5 Wm.
This resulted in a £ow of approximately 20^50 nl/min when a capil-
lary voltage of about 1.3 kV was applied. Desolvation was facilitated
by a nitrogen counter-current drying gas. The cone voltage was set at
40 V. For the acquisition of collision-induced dissociation (CID) spec-
tra, the collision energy was optimized in the range 60^120 eV. Argon
was used as the collision gas.
When necessary, contaminants and salts were removed from the
samples by perfusion chromatography using micro-columns (200 nl
bed volume) packed with POROS R3 (PE-Biosystems). Normally, 5 Wl
of sample was applied to the resin followed by washing with 30 Wl
0.1% TFA and elution directly into the nano-spray needle with 60%
CH3CN containing 1% acetic acid.
3. Results
The deconvoluted ES mass spectrum of PRP-1 shows two
major peaks at 15 514 Da and 15 690 Da, a mass separation of
176 Da (Fig. 2). Similarly, the mass spectrum of PRP-3 re-
vealed two peaks, at 11 161 Da and 11 337 Da, also a mass
separation of 176 Da. The 176 Da mass di¡erence is diagnos-
tic for a hexuronic acid conjugating group which means glu-
curonic acid or an isomer to glucuronic acid (e.g. galacturonic
acid). The lower mass peaks correspond to PRP-1 and PRP-3
with an N-terminal pyroglutamic acid and phosphorylations
of Ser-8 and Ser-22 [3^5].
Tryptic digestion of PRP-1 generated eight peptides of
which six corresponded to residues 31^150 (T2^T7) (Figs. 1
and 3). The other two peptides both corresponded to residues
1^30 i.e. T1 and T1+176 Da. Tryptic digestion of PRP-3 gen-
erated ¢ve peptides, three of which covered residues 31^106.
Similarly, the two peptides corresponding to residues 1^30
had a mass di¡erence of 176 Da. The ¢ve tryptic peptides
observed in the spectrum of PRP-3 were identical to their
counterparts found in the spectrum of PRP-1, compatible
with the fact that PRP-3 is a C-terminally truncated form of
PRP-1.
The proportions of the two forms of N-terminal tryptic
peptide in the digest of PRP-1 were determined by reverse
phase HPLC (Fig. 4). After collection and mass spectrometric
analysis, the early eluting component was found to represent
the higher mass peptide (triply charged ion at monoisotopic
m/z 1233.1 (T1+176 Da), corresponding to a mass of 3696 Da)
while the later eluting component was 176 Da lighter (triply
charged ion at monoisotopic m/z 1174.4 (T1), corresponding
to a mass of 3520 Da). The heavy (+176 Da) and the light
form of the PRP-1 N-terminal fragment were present in the
Fig. 2. Maximum entropy derived mass spectrum showing the two forms of PRP-1 that di¡er by 176 Da.
Fig. 3. Nano-ES mass spectrum of the complete tryptic digest of PRP-1. The proteolytic peptides are indicated T1^T7 and are also labeled with
their respective charge.
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proportions 42 and 58%, respectively (Fig. 4). The proportion
shifted in favor of the lighter form (3520 Da) under storage in
acidic solution (pH 2^3), indicating loss of 176 Da.
The two N-terminal tryptic peptides of PRP-1, triply
charged at m/z 1174.4 and 1233.1, were further analyzed by
CID (Fig. 5). The product^ion spectrum of the lighter precur-
sor, triply charged at m/z 1174.4, showed serine residues 8 and
22 to be phosphorylated by the y-ion series following y9 and
y223 (Fig. 5A) [13,14]. The y

9 and succeeding y
-ions were 80
Th heavier than those which would be obtained in the absence
of phosphorylation at Ser-22. From y223 and above, the y
2-
ions were 80 Th heavier (i.e. 160 Da) than in an equivalent
non-modi¢ed peptide, showing Ser-8 to also be phosphorylat-
ed. A series of b3 ^b

7 ions was observed, indicating that the
N-terminal residue was pyroglutamic acid. All higher b-ions
were consistent with this ¢nding. The b-ion series was com-
patible with Ser-8 being phosphorylated but did not extend to
residue 22. To con¢rm that the serine residues were indeed
phosphorylated as opposed to being sulfated, the doubly de-
protonated peptide was analyzed in the negative ion mode.
The CID spectrum (Fig. 5A, inset) showed a peak at m/z
78.9 characteristic of the PO3-group. The CID spectrum of
the heavier N-terminal peptide, triply charged at m/z 1233.1,
showed b- and y-type ions that were identical to those of the
lighter form in the low m/z range (Fig. 5B). The additional
modi¢cation by glucuronic acid was found to be located to
Ser-17 by a shift of 53 Da in the y-ion series following y214 .
Fig. 4. Reverse phase HPLC of the two N-terminal tryptic peptides
of PRP-1 (section of chromatogram). The early eluting component
corresponds to the heavier N-terminal tryptic fragment (3696 Da)
whereas the later eluting component corresponds to the lighter form
(3520 Da). The proportions of the peak areas are 42 and 58%, re-
spectively.
Fig. 5. CID spectra of the two N-terminal peptides generated via tryptic cleavage of PRP-1. A: The CID spectrum of the lighter N-terminal
fragment (T1), triply charged at monoisotopic m/z 1174.4. B: The CID spectrum of the heavier N-terminal fragment (T1+176 Da), triply
charged at monoisotopic m/z 1233.1. The inset in A shows the CID spectrum of the doubly deprotonated fragment T1 analyzed in the negative
ion mode.
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The 53 Da shift corresponds to a cleavage after the 3rd and
the 5th carbon atoms in glucuronic acid with concomitant loss
of two water molecules (3;5X132H2O) [15]. Further evidence
for a glucuronic acid conjugation are the characteristic mass
losses from the precursor ion that are indicated in Fig. 5B.
4. Discussion
We present mass spectrometric evidence for a novel post-
translational modi¢cation of acidic PRPs by an O-linked hex-
uronic acid (i.e. glucuronic acid or an isomer) at Ser-17 in
addition to an N-terminal pyroglutamic acid residue and
phosphorylations at Ser-8 and Ser-22. The N-terminal pyro-
glutamic acid and the phosphorylations are known in acidic
PRPs [5] and may contribute to their innate immunity proper-
ties [1,2]. However, to our knowledge this is the ¢rst structural
evidence for a glycosylation of human acidic PRPs and for an
O-glucuronidation of a serine residue.
The present ¢ndings indicate that about 40% of PRP-1 and
PRP-3 carry a glucuronic acid residue O-linked to Ser-17. The
mass di¡erence of 176 Da of the two forms of PRP-1 and
PRP-3 is indicative for glucuronic acid conjugation. Ions di-
agnostic for this modi¢cation and its location to Ser-17 were
also present in the CID spectra. Furthermore, the loss of the
176 Da modi¢cation in acidic environment is consistent with
the behavior of carboxylic acid sugars [9]. Glucuronic acid is
commonly found in human proteoglycans [9]. It has also been
reported in acidic PRPs from rats treated with a L-adrenergic
agonist (isoproterenol) [11] but has not been studied in normal
rats or localized to the position now found in human PRP.
However, neither glucuronic nor hexuronic acid O-linked to
Ser have so far been demonstrated in human glycoproteins
[9].
Drugs, such as L2-adrenergic agonists, are metabolized by
glucuronidation [16], and L-adrenergic agonists (isoprotere-
nol) enhance rat salivary gland PRP [17] and parotid proteo-
glycan synthesis [18]. One of the three saliva donors su¡ered
from psoriasis and asthma which are diseases associated with
altered glycosylation patterns [19,20]. This subject was also
medicated with a L2-adrenergic agonist intermittently. Such
individual di¡erences or a post-translational modi¢cation
that, similar to truncation of PRP-1, a¡ects only a subset of
molecules may explain the occurrence of O-glucuronidation in
about 40% of the acidic PRPs. Functionally, O-glycosylation
of the N-terminal domain of acidic PRPs may interfere with
its Ca-binding and hydroxyapatite adsorption properties or
introduce properties typical of glycoproteins such as resistance
to proteolysis and ligand binding [9].
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